Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The strategic communications Company announced its unaudited interim results for the six months ended 30 June, which included record profit for a six-month period with record revenue and profit expected for the full year.</li>
<li>The profit before tax, excluding non-trading foreign exchange gains and losses, increased 200% to £1.5m for the Period (H1 2025: £0.5m), the highest profit achieved in any six-month period since its Admission to AIM in 2002.</li>
<li>On 26 March 2025, the Company announced that it would be changing its year end from 30 June to 31 December and accordingly would be extending the year ending 30 June 2025 to an 18-month period running from 1 July 2024 to 31 December 2025. </li>
</ul>


The strategic communications Company announced its unaudited interim results for the six months ended 30 June, which included record profit for a six-month period with record revenue and profit expected for the full year.
The profit before tax, excluding non-trading foreign exchange gains and losses, increased 200% to £1.5m for the Period (H1 2025: £0.5m), the highest profit achieved in any six-month period since its Admission to AIM in 2002.
On 26 March 2025, the Company announced that it would be changing its year end from 30 June to 31 December and accordingly would be extending the year ending 30 June 2025 to an 18-month period running from 1 July 2024 to 31 December 2025. 


DXS International Plc - Small Cap Feast: 22 September 2026

<ul>
<li>FY ’27 will be another year of transition, but the prospects for a new contract-led increase in net profits in FY ’28 are amplified by two price increases that DXS is planning to implement on its main SmartReferral offering between April and October 2027 (respectively, a consumer price index-related increase and a product price increase).</li>
<li>The pharmaceutical ‘ad’ business should also benefit from a price increase, new products, and demand from new customers who have been secured over the course of the last five months.</li>
<li>With FY ’26 providing a solid base from which to build, we would suggest that the current market capitalisation to sales ratio of 0.44x is undervaluing DXS on a number of fronts: 1) Its intellectual property; 2) current recurring revenue stream from referral software embedded into GP (General Practitioner) workstreams; 3) 86.9% gross profit margin; and 4) the potential for good net profit growth over the next two years.</li>
</ul>


FY ’27 will be another year of transition, but the prospects for a new contract-led increase in net profits in FY ’28 are amplified by two price increases that DXS is planning to implement on its main SmartReferral offering between April and October 2027 (respectively, a consumer price index-related increase and a product price increase).
The pharmaceutical ‘ad’ business should also benefit from a price increase, new products, and demand from new customers who have been secured over the course of the last five months.
With FY ’26 providing a solid base from which to build, we would suggest that the current market capitalisation to sales ratio of 0.44x is undervaluing DXS on a number of fronts: 1) Its intellectual property; 2) current recurring revenue stream from referral software embedded into GP (General Practitioner) workstreams; 3) 86.9% gross profit margin; and 4) the potential for good net profit growth over the next two years.


<ul><li>DXS International PLC (AQSE:DXSP) yesterday released a trading update for the financial year to 30 April 2026.</li><li>We have published research on this which is attached and a snapshot of the research is below.</li><li> The April 2026 turnover is in line with our forecast of £3.4m which is marginally lower than the previous period.</li></ul>

DXS International PLC (AQSE:DXSP) yesterday released a trading update for the financial year to 30 April 2026.We have published research on this which is attached and a snapshot of the research is below. The April 2026 turnover is in line with our forecast of £3.4m which is marginally lower than the previous period.

Hybridan Research: DXS International plc (AQSE:DXSP)

<ul><li>2nd July 2026 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP.</li><li>** Potential means Intention to Float (ITF) or similar announcement has been made.</li><li>***Arranged by type of listing and date of announcement.</li></ul>

2nd July 2026 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP.** Potential means Intention to Float (ITF) or similar announcement has been made.***Arranged by type of listing and date of announcement.

DXS International PLC - Hybridan Small Cap Feast: 2 July 2026

<ul>
<li>The Interims to 31 October 2025 reported a 2% decrease in Revenue to £1,685k and a 5% reduction in Administration Expenses to £1,618k, while Gross Margins improved marginally to 87%.</li>
<li>Given the general inflationary background, the lower administration costs suggest strong operational control and discipline.</li>
<li>The interim loss after tax rose to £99k from a £1k profit last year, which is largely due to a £164k reduction in Grant Income and £5k less in R&amp;D tax credit. </li>
</ul>


The Interims to 31 October 2025 reported a 2% decrease in Revenue to £1,685k and a 5% reduction in Administration Expenses to £1,618k, while Gross Margins improved marginally to 87%.
Given the general inflationary background, the lower administration costs suggest strong operational control and discipline.
The interim loss after tax rose to £99k from a £1k profit last year, which is largely due to a £164k reduction in Grant Income and £5k less in R&amp;D tax credit. 


United Kingdom

DXS International Plc is a healthcare IT company that develops and distributes clinical decision support solutions for general practitioners, nurses, and retail pharmacies. The company offers products such as Point-of-Care, ExpertCare, and Smarts Referrals Solution, which provide up-to-date medical information and streamline patient care. DXS International Plc was incorporated in 2007 and is based in Elstead, United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

DXS International (DXSP PZ)

DXS International Plc - Small Cap Feast: 22 September 2026

The strategic communications Company announced its unaudited interim results for the six months ended 30 June, which included record profit for a...

Hybridan

Hybridan Research: DXS International

DXS International PLC (AQSE:DXSP) today announced its annual results for the year ended 30 April 2026. We have published research on this which is...

Hybridan

Hybridan Research: DXS International plc (AQSE:DXSP)

DXS International PLC (AQSE:DXSP) yesterday released a trading update for the financial year to 30 April 2026. We have published research on this...

Hybridan

DXS International PLC - Hybridan Small Cap Feast: 2 July 2026

2nd July 2026 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan...

Hybridan

Hybridan Research: DXS International PLC

The Interims to 31 October 2025 reported a 2% decrease in Revenue to £1,685k and a 5% reduction in Administration Expenses to £1,618k, while Gross...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)